Reading VTGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VTGN free→Reading VTGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VTGN free→QuarterlyIQ Insights · VTGN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 18, 2026 (the “ Effective Date ”), Vistagen Therapeutics, Inc. (the “ Company ”) appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer. Dr. Angelov, age 57, served as Chief Medical Officer at Theranica, a neuromodulation therapeutics company, from October 2024 to May 2026. Prior to Theranica, Dr. Angelov serve…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 7, 2026, the Compensation Committee of the Board of Directors of Vistagen Therapeutics, Inc. (the “ Company ”), in consultation with the Company’s independent compensation consultant, approved of retention awards in the form of a stock option grant (the “ Options ”) to all Company employees, including the following executives who each rece…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Re…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. On March 17, 2026, Mary Rotunno resigned from the Board of Directors of Vistagen Therapeutics, Inc., effective April 1, 2026. Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc.…
Other Events On March 5, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) implemented a Board approved reduction in its workforce by approximately 20%. The reduction is intended to provide disciplined cash management while prioritizing efficient execution of ongoing clinical studies in the Company’s PALISADE Program for fasedienol for the acute treatment of social anxiety disorder. The Company expects topline results from its PALISADE-4 Phase 3 trial in the first half of 2026 and expects c…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. On February 13, 2026, Paul Edick resigned from the Board of Directors (the “ Board ”) of Vistagen Therapeutics, Inc. (the “ Company ”). The Company is actively seeking new candidates to fill the resulting vacancy on the Board. Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report…
Results of Operations and Financial Condition. On February 12, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2026 third quarter ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” f…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 3, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“ Common Stock ”), for the last 30 consecutive business days, the Company is not currently in complianc…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 28, 2025, the Board of Directors of Vistagen Therapeutics, Inc. (the “ Company ”) appointed Nick B. Tressler to serve as the Company’s Chief Financial Officer and Treasurer, effective December 1, 2025 (the “ Effective Date ”). Mr. Tressler was also appointed as the Company’s principal financial and accounting officer. Mr. Tressler, age…
Results of Operations and Financial Condition. On November 13, 2025, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2026 second quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed”…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 27, 2025, the Board of Directors (the “ Board ”) of Vistagen Therapeutics, Inc. (the “ Company ”), upon recommendation from the Corporate Governance and Nominating Committee of the Board, unanimously approved of the appointment of Mr. Paul R. Edick as a director to serve until the Company’s next annual meeting of stockholders or until hi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2025, Vistagen Therapeutics, Inc. (the “ Company ”) received notice from Cynthia L. Anderson, the Company’s Chief Financial Officer and principal financial and accounting officer, of her decision to resign from the Company effective October 15, 2025. Ms. Anderson’s decision to resign is not the result of any disagreement with the C…
Results of Operations and Financial Condition. On August 7, 2025, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2026 first quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 25, 2025, Vistagen Therapeutics, Inc. (the “ Company ”) announced the appointment of Ms. Elissa Cote as the Company’s Chief Corporate Development Officer, effective June 23, 2025. A copy of the press release announcing Ms. Cote’s appointment is attached to this Current Report on Form 8-K as Exhibit 99.1. Ms. Cote, age 50, brings seasoned le…
Results of Operations and Financial Condition. On February 13, 2025, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2025 third quarter ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'inexpensive' to 'fair'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.